Winkler Gábor, Kis János Tibor, Arapovicsné Kiss Krisztina, Schandl László
1 Észak-budai Szent János Centrumkórház, II. Belgyógyászat-Diabetológia Budapest, Diós árok 1-3., 1125 Magyarország.
2 Miskolci Egyetem, Egészségtudományi Kar, Elméleti Egészségtudományi Intézet Miskolc Magyarország.
Orv Hetil. 2023 Oct 22;164(42):1656-1664. doi: 10.1556/650.2023.32894.
Following the introduction of mono- and then dual hormone (incretin) receptor agonists into therapy, attention was turned to multiple receptor stimulation, with the additional activation of the glucagon receptor, as a new option for the pharmaceutical treatment of type 2 diabetes and obesity. In addition to its role in carbohydrate metabolism, the article reviews the other important physiological tasks of glucagon, especially its participation in intrainsular paracrine regulation, energy expenditure and the shaping of appetite and food consumption. It covers the potential benefits of the triple combination and briefly touches data on the efficacy and safety of the first triple receptor agonist drug, retatrutide, in preclinical human studies. Further confirmation of the promising results may represent progress in the treatment of these forms of disease and their accompanying conditions, such as steatosis hepatis. Orv Hetil. 2023; 164(42): 1656-1664.
在将单激素和双激素（肠促胰岛素）受体激动剂引入治疗后，人们的注意力转向了多受体刺激，即额外激活胰高血糖素受体，将其作为2型糖尿病和肥胖症药物治疗的新选择。除了其在碳水化合物代谢中的作用外，本文还综述了胰高血糖素的其他重要生理功能，尤其是其参与胰岛内旁分泌调节、能量消耗以及食欲和食物摄入的形成。文章涵盖了三联疗法的潜在益处，并简要提及了首个三联受体激动剂药物瑞他鲁肽在临床前人体研究中的疗效和安全性数据。这些有前景的结果若能得到进一步证实，可能代表着在治疗这些疾病形式及其伴随病症（如肝脂肪变性）方面取得进展。《匈牙利医学周报》。2023年；164(42): 1656 - 1664。
